BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 18164847)

  • 1. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118).
    Knisely JP; Berkey B; Chakravarti A; Yung AW; Curran WJ; Robins HI; Movsas B; Brachman DG; Henderson RH; Mehta MP
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):79-86. PubMed ID: 18164847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study.
    Buchsbaum JC; Suh JH; Lee SY; Chidel MA; Greskovich JF; Barnett GH
    Cancer; 2002 Apr; 94(8):2265-72. PubMed ID: 12001126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118.
    Corn BW; Moughan J; Knisely JP; Fox SW; Chakravarti A; Yung WK; Curran WJ; Robins HI; Brachman DG; Henderson RH; Mehta MP; Movsas B
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):71-8. PubMed ID: 18164829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linac radiosurgery versus whole brain radiotherapy for brain metastases. A survival comparison based on the RTOG recursive partitioning analysis.
    Kocher M; Maarouf M; Bendel M; Voges J; Müller RP; Sturm V
    Strahlenther Onkol; 2004 May; 180(5):263-7. PubMed ID: 15127155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A boost in addition to whole-brain radiotherapy improves patient outcome after resection of 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients.
    Rades D; Pluemer A; Veninga T; Dunst J; Schild SE
    Cancer; 2007 Oct; 110(7):1551-9. PubMed ID: 17654659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients.
    Rades D; Bohlen G; Pluemer A; Veninga T; Hanssens P; Dunst J; Schild SE
    Cancer; 2007 Jun; 109(12):2515-21. PubMed ID: 17487853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of short-course versus long-course whole-brain radiotherapy in the treatment of brain metastases.
    Rades D; Bohlen G; Dunst J; Lohynska R; Veninga T; Stalpers L; Schild SE; Dahm-Daphi J
    Strahlenther Onkol; 2008 Jan; 184(1):30-5. PubMed ID: 18188520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recursive partitioning analysis (RPA) class does not predict survival in patients with four or more brain metastases.
    Nieder C; Andratschke N; Grosu AL; Molls M
    Strahlenther Onkol; 2003 Jan; 179(1):16-20. PubMed ID: 12540980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A matched-pair analysis comparing whole-brain radiotherapy plus stereotactic radiosurgery versus surgery plus whole-brain radiotherapy and a boost to the metastatic site for one or two brain metastases.
    Rades D; Kueter JD; Pluemer A; Veninga T; Schild SE
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1077-81. PubMed ID: 18707817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential impact of whole-brain radiotherapy added to radiosurgery for brain metastases.
    Kong DS; Lee JI; Im YS; Nam DH; Park K; Kim JH
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):385-9. PubMed ID: 20097485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients.
    Rades D; Lohynska R; Veninga T; Stalpers LJ; Schild SE
    Cancer; 2007 Dec; 110(11):2587-92. PubMed ID: 17893909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.
    Mehta MP; Shapiro WR; Phan SC; Gervais R; Carrie C; Chabot P; Patchell RA; Glantz MJ; Recht L; Langer C; Sur RK; Roa WH; Mahe MA; Fortin A; Nieder C; Meyers CA; Smith JA; Miller RA; Renschler MF
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1069-76. PubMed ID: 18977094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first : result of a randomized pilot study.
    Lee DH; Han JY; Kim HT; Yoon SJ; Pyo HR; Cho KH; Shin SH; Yoo H; Lee SH; Lee JS
    Cancer; 2008 Jul; 113(1):143-9. PubMed ID: 18459180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database.
    Shaw E; Scott C; Suh J; Kadish S; Stea B; Hackman J; Pearlman A; Murray K; Gaspar L; Mehta M; Curran W; Gerber M
    J Clin Oncol; 2003 Jun; 21(12):2364-71. PubMed ID: 12805339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-brain radiotherapy with 20 Gy in 5 fractions for brain metastases in patients with cancer of unknown primary (CUP).
    Rades D; Bohlen G; Lohynska R; Veninga T; Stalpers LJ; Schild SE; Dunst J
    Strahlenther Onkol; 2007 Nov; 183(11):631-6. PubMed ID: 17960339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do patients receiving whole-brain radiotherapy for brain metastases from renal cell carcinoma benefit from escalation of the radiation dose?
    Rades D; Heisterkamp C; Schild SE
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):398-403. PubMed ID: 20488627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score.
    Le Scodan R; Massard C; Mouret-Fourme E; Guinebretierre JM; Cohen-Solal C; De Lalande B; Moisson P; Breton-Callu C; Gardner M; Goupil A; Renody N; Floiras JL; Labib A
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):839-45. PubMed ID: 17544592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.
    Mehta MP; Rodrigus P; Terhaard CH; Rao A; Suh J; Roa W; Souhami L; Bezjak A; Leibenhaut M; Komaki R; Schultz C; Timmerman R; Curran W; Smith J; Phan SC; Miller RA; Renschler MF
    J Clin Oncol; 2003 Jul; 21(13):2529-36. PubMed ID: 12829672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases.
    Kocher M; Eich HT; Semrau R; Güner SA; Müller RP
    Strahlenther Onkol; 2005 Jan; 181(1):20-5. PubMed ID: 15660189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of overall treatment time in patients irradiated for more than three brain metastases.
    Rades D; Kieckebusch S; Lohynska R; Veninga T; Stalpers LJ; Dunst J; Schild SE
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1509-13. PubMed ID: 17689033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.